» Articles » PMID: 26462866

Retinoic Acid Receptor β2 Agonists Restore Glycaemic Control in Diabetes and Reduce Steatosis

Overview
Specialty Endocrinology
Date 2015 Oct 15
PMID 26462866
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To investigate the effects of specific retinoic acid receptor (RAR) agonists in diabetes and fatty liver disease.

Methods: Synthetic agonists for RARβ2 were administered to wild-type (wt) mice in a model of high-fat-diet (HFD)-induced type 2 diabetes (T2D) and to ob/ob and db/db mice (genetic models of obesity-associated T2D).

Results: We show that administration of synthetic agonists for RARβ2 to either wt mice in a model of HFD-induced T2D or to ob/ob and db/db mice reduces hyperglycaemia, peripheral insulin resistance and body weight. Furthermore, RARβ2 agonists dramatically reduce steatosis, lipid peroxidation and oxidative stress in the liver, pancreas and kidneys of obese, diabetic mice. RARβ2 agonists also lower levels of mRNAs involved in lipogenesis, such as sterol regulatory element-binding transcription factor 1 (SREBP1) and fatty acid synthase, and increase mRNAs that mediate mitochondrial fatty acid β-oxidation, such as CPT1α, in these organs. RARβ2 agonists lower triglyceride levels in these organs, and in muscle.

Conclusions: Collectively, our data show that orally active, rapid-acting, high-affinity pharmacological agonists for RARβ2 improve the diabetic phenotype while reducing lipid levels in key insulin target tissues. We suggest that RARβ2 agonists should be useful drugs for T2D therapy and for treatment of hepatic steatosis.

Citing Articles

Retinoic Acid Improves Vascular Endothelial Dysfunction by Inhibiting PI3K/AKT/YAP-mediated Ferroptosis in Diabetes Mellitus.

Zhang M, Liu Y, Liu Y, Tang B, Wang H, Lu M Curr Pharm Des. 2024; 31(2):140-152.

PMID: 39350421 DOI: 10.2174/0113816128313964240728155100.


Targeting nuclear receptors for NASH/MASH: From bench to bedside.

Sinha R Liver Res. 2024; 8(1):34-45.

PMID: 38544909 PMC: 7615772. DOI: 10.1016/j.livres.2024.03.002.


Regulation and targeting of SREBP-1 in hepatocellular carcinoma.

Su F, Koeberle A Cancer Metastasis Rev. 2023; 43(2):673-708.

PMID: 38036934 PMC: 11156753. DOI: 10.1007/s10555-023-10156-5.


The Cxcr2 subset of the S100a8 gastric granylocytic myeloid-derived suppressor cell population (G-MDSC) regulates gastric pathology.

Kao K, Grasberger H, El-Zaatari M Front Immunol. 2023; 14:1147695.

PMID: 37744359 PMC: 10514515. DOI: 10.3389/fimmu.2023.1147695.


International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.


References
1.
Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74. DOI: 10.1111/j.1572-0241.1999.01377.x. View

2.
Lenhard J . Lipogenic enzymes as therapeutic targets for obesity and diabetes. Curr Pharm Des. 2011; 17(4):325-31. DOI: 10.2174/138161211795164185. View

3.
Martin M, Gallego-Llamas J, Ribes V, Kedinger M, Niederreither K, Chambon P . Dorsal pancreas agenesis in retinoic acid-deficient Raldh2 mutant mice. Dev Biol. 2005; 284(2):399-411. DOI: 10.1016/j.ydbio.2005.05.035. View

4.
Kim S, Kim C, Axe D, Cook A, Lee M, Li T . All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade. Hepatology. 2013; 59(5):1750-60. PMC: 4008145. DOI: 10.1002/hep.26699. View

5.
Gudas L . Emerging roles for retinoids in regeneration and differentiation in normal and disease states. Biochim Biophys Acta. 2011; 1821(1):213-21. PMC: 3237723. DOI: 10.1016/j.bbalip.2011.08.002. View